Nitazoxanide/Camostat combination for COVID-19: An unexplored potential therapy
Keywords:Hypercoagulability, Covid drugs, Repurposing drugs, Corana virus, SARS, respiratory disease, Cytokines
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19) and its ripple effects has brought major challenges to worldwide health systems. Urgent strategies are required to manage this pandemic and repurposing of existing drugs offer an option forward. A combination drug therapy for COVID-19 aims to prevent both the virus entry/spread as well as quelling the immune system havocs that the virus wreaks in the human body. This article analyzes Nitazoxanide/Camostat combination for their potential activity against SARS-CoV-2. Nitazoxanide, FDA approved drug potentiates host antiviral response, thereby reducing viral replication, titer and ensuing immune dysregulation. Camostat, a potent serine protease inhibitor blocks viral cell entry along with the potential to decrease COVID-19-associated hypercoagulability. Both the drugs do not inhibit cyp P450 enzymes and could be co-administered. Based on the combined pathophysiological and pharmacological potential, the drugs combination potentially recommended for early evaluation and clinical trials of this combination.
How to Cite
Rights and Permission
The copyright holder for contents - ScienceIn
Permission: The readers can re-use the graphics and images for educational and academic purpose (for reproduction in Review etc) provided that source reference is cited properly.